https://mindmedicinelaw.com/briefing/speech-dynamics-in-psilocybin-therapy-for-ptsd-new-insights-20260716-22979The Psychedelic Journalen2026-07-17T15:06:08.547621+00:00Speech Dynamics in Psilocybin Therapy for PTSD: New Insightspsilocybin therapy, PTSD treatment, speech dynamics, psychedelic-assisted therapy, clinical trials, Compass Pathfinder Ltd, non-directive support, introspective states, therapeutic protocolshttps://mindmedicinelaw.com/briefing/ketamine-therapy-gains-traction-in-iowa-amid-depression-treatment-challenges-20260716-22907The Psychedelic Journalen2026-07-16T22:05:30.429260+00:00Ketamine Therapy Gains Traction in Iowa Amid Depression Treatment Challengesketamine therapy, depression treatment, psychedelic-assisted therapy, mental health care, Iowa, regulation, access to treatment, long-term efficacy, psychedelic researchhttps://mindmedicinelaw.com/briefing/fda-guidance-may-reshape-psychedelic-trials-in-the-us-20260716-22904The Psychedelic Journalen2026-07-16T22:04:42.118565+00:00FDA Guidance May Reshape Psychedelic Trials in the USFDA guidance, psychedelic trials, clinical trial design, drug development, psychedelic research, psilocybin, MDMA, regulatory framework, participant safety, therapeutic potentialhttps://mindmedicinelaw.com/briefing/clia-regulations-update-implications-for-psychedelic-research-20260716-22610The Psychedelic Journalen2026-07-16T15:06:34.838936+00:00CLIA Regulations Update: Implications for Psychedelic ResearchCLIA regulations, psychedelic research, clinical trials, laboratory standards, biosafety, cybersecurity, CMS, CDC, laboratory testing, RFIhttps://mindmedicinelaw.com/briefing/medicare-2027-policies-implications-for-psychedelic-therapies-20260716-22593The Psychedelic Journalen2026-07-16T15:06:19.261266+00:00Medicare 2027 Policies: Implications for Psychedelic TherapiesMedicare 2027, psychedelic therapies, payment policies, healthcare landscape, reimbursement, emerging treatments, clinical evidence, regulatory approval, healthcare policy, stakeholder advocacyhttps://mindmedicinelaw.com/briefing/ketamine-therapy-for-veterans-faces-funding-challenges-20260715-22908The Psychedelic Journalen2026-07-17T22:05:03.811994+00:00Ketamine Therapy for Veterans Faces Funding Challengesketamine therapy, veterans, PTSD, depression, mental health, funding cuts, VA, glutamate system, antidepressant, policy implicationshttps://mindmedicinelaw.com/briefing/anchor-framework-s-role-in-psychedelic-assisted-therapy-20260715-22820The Psychedelic Journalen2026-07-17T22:04:54.981029+00:00ANCHOR Framework's Role in Psychedelic-Assisted Therapypsychedelic-assisted therapy, ANCHOR framework, facilitator competencies, therapeutic accompaniment, complex systems, psilocybin, integration, neuroscience, therapeutic alliance, ethicshttps://mindmedicinelaw.com/briefing/white-matter-signals-new-insights-in-brain-monitoring-20260715-23003The Psychedelic Journalen2026-07-17T15:06:24.733017+00:00White Matter Signals: New Insights in Brain Monitoringwhite matter signals, electrophysiological features, brain monitoring, drug-resistant epilepsy, stereo-electroencephalography, signal complexity, fractional anisotropy, cognitive control taskhttps://mindmedicinelaw.com/briefing/psychotropic-drug-monitoring-in-bariatric-surgery-patients-20260715-23014The Psychedelic Journalen2026-07-17T15:06:17.291792+00:00Psychotropic Drug Monitoring in Bariatric Surgery Patientspsychotropic drugs, bariatric surgery, therapeutic drug monitoring, psychiatric decompensation, drug exposure changes, pharmacokinetics, lithium, tricyclic antidepressants, clozapine, clinical trialshttps://mindmedicinelaw.com/briefing/ctbs-reduces-relapse-in-alcohol-use-disorder-clinical-trial-insights-20260715-22959The Psychedelic Journalen2026-07-17T15:05:47.120247+00:00cTBS Reduces Relapse in Alcohol Use Disorder: Clinical Trial Insightscontinuous theta-burst stimulation, alcohol use disorder, neuromodulation, relapse prevention, neural networks, gene expression, clinical trial, neuroplasticity, brain stimulation, addiction treatmenthttps://mindmedicinelaw.com/briefing/psilocybin-and-synaptic-plasticity-contextual-effects-in-therapy-20260715-22961The Psychedelic Journalen2026-07-17T15:05:35.848985+00:00Psilocybin and Synaptic Plasticity: Contextual Effects in Therapypsilocybin, synaptic plasticity, psychedelic therapy, environmental context, neuroplasticity, clinical trials, brain plasticity, therapeutic setting, psychedelic research, mental healthhttps://mindmedicinelaw.com/briefing/sex-dependent-effects-of-psychedelics-insights-from-rodent-models-20260715-22786The Psychedelic Journalen2026-07-16T22:05:21.058322+00:00Sex-Dependent Effects of Psychedelics: Insights from Rodent Modelssex-dependent effects, psychedelics, rodent models, 5-HT2A receptor, neuroplasticity, clinical applications, personalized therapies, pharmacodynamics, serotonergic signaling, disease modelshttps://mindmedicinelaw.com/briefing/challenges-in-schizophrenia-drug-discovery-animal-models-under-scrutiny-20260714-22824The Psychedelic Journalen2026-07-17T22:05:36.609953+00:00Challenges in Schizophrenia Drug Discovery: Animal Models Under Scrutinyschizophrenia research, animal models, drug discovery, human biomarkers, neurophysiology, clinical relevance, in vitro models, in silico models, collaboration, therapeutic developmenthttps://mindmedicinelaw.com/briefing/zero-prediction-errors-in-neural-processing-and-psychedelics-20260714-22825The Psychedelic Journalen2026-07-17T22:05:28.666350+00:00Zero Prediction Errors in Neural Processing and Psychedelicszero prediction errors, reinforcement learning, neural processing, psychedelic research, affect and belief updating, EEG analyseshttps://mindmedicinelaw.com/briefing/dmt-immersion-study-neuroscience-insights-and-limits-20260714-22903The Psychedelic Journalen2026-07-17T22:05:21.816800+00:00DMT Immersion Study: Neuroscience Insights and LimitsDMT, psychedelic research, consciousness, clinical applications, phenomenology, serotonin receptors, mental health, policy implications, psychedelic therapy, regulatory frameworkshttps://mindmedicinelaw.com/briefing/dietary-supplement-use-for-mood-in-poland-a-public-health-concern-20260714-22791The Psychedelic Journalen2026-07-17T22:05:11.782921+00:00Dietary Supplement Use for Mood in Poland: A Public Health Concerndietary supplements, mood improvement, stress relief, Poland, healthcare communication, nutrivigilance, patient education, drug interactions, public health, self-medicationhttps://mindmedicinelaw.com/briefing/psilocybin-s-dual-role-therapy-and-spirituality-explored-20260714-22463The Psychedelic Journalen2026-07-16T15:07:13.450623+00:00Psilocybin's Dual Role: Therapy and Spirituality Exploredpsilocybin, therapeutic potential, spiritual practices, neuroplasticity, shamanic traditions, psychedelic-assisted therapy, mental health, clinical psychiatry, cultural integration, ethical considerationshttps://mindmedicinelaw.com/briefing/psilocybin-s-therapeutic-and-spiritual-potential-a-scholarly-analysis-20260714-22462The Psychedelic Journalen2026-07-16T15:07:06.045797+00:00Psilocybin's Therapeutic and Spiritual Potential: A Scholarly Analysispsilocybin research, therapeutic potential, spiritual practices, neuroplasticity, mental health, psychedelic renaissance, psychopharmacology, ancient traditions, psychiatric care, clinical protocolshttps://mindmedicinelaw.com/briefing/ketamine-therapy-at-imh-a-new-hope-for-depression-in-singapore-20260714-22405The Psychedelic Journalen2026-07-16T15:06:58.125065+00:00Ketamine Therapy at IMH: A New Hope for Depression in Singaporeketamine therapy, treatment-resistant depression, Institute of Mental Health, psychedelic therapies, mental health care, Singapore mental healthhttps://mindmedicinelaw.com/briefing/eeg-based-ml-predicts-anxiety-in-adolescents-with-mdd-20260714-22623The Psychedelic Journalen2026-07-16T15:06:44.899986+00:00EEG-Based ML Predicts Anxiety in Adolescents with MDDEEG, machine learning, adolescent mental health, major depressive disorder, comorbid anxiety, personalized diagnostics, translational psychiatry, biomarker-based diagnosticshttps://mindmedicinelaw.com/briefing/federal-agencies-back-psychedelics-fda-and-hrsa-lead-20260713-22905The Psychedelic Journalen2026-07-16T22:05:11.638631+00:00Federal Agencies Back Psychedelics: FDA and HRSA LeadFDA, HRSA, psychedelic research, breakthrough therapy, mental health, psilocybin, MDMA, clinical trials, federal policy, market opportunitieshttps://mindmedicinelaw.com/briefing/fda-finalizes-psychedelic-research-guidance-sets-hearing-20260713-22906The Psychedelic Journalen2026-07-16T22:05:00.673376+00:00FDA Finalizes Psychedelic Research Guidance, Sets HearingFDA guidance, psychedelic research, therapeutic uses, clinical trials, mental health, policy implications, safety monitoring, psilocybin, MDMA, regulatory frameworkhttps://mindmedicinelaw.com/briefing/va-hhs-launch-psychedelic-therapy-for-veterans-20260713-22909The Psychedelic Journalen2026-07-16T22:04:51.753736+00:00VA & HHS Launch Psychedelic Therapy for Veteranspsychedelic therapies, veteran mental health, VA and HHS partnership, psilocybin, MDMA, federal policy, PTSD treatment, mental health innovation, Schedule I substances, clinical trialshttps://mindmedicinelaw.com/briefing/epigenetic-effects-of-psychedelics-and-ketamine-implications-for-therapy-20260710-23047The Psychedelic Journalen2026-07-17T15:05:58.071097+00:00Epigenetic Effects of Psychedelics and Ketamine: Implications for Therapyepigenetic changes, psychedelics, ketamine, mental health treatment, neuromodulation, clinical trials, DNA methylation, histone modification, therapeutic strategies, psychedelic-assisted therapy